Group 1 - The core point of the article is that Zhixiang Jintai (688443.SH) has signed exclusive cooperation agreements with subsidiaries of Kangzhe Pharmaceutical for two monoclonal antibody injections, which will enhance the company's performance and long-term development [1] Group 2 - Zhixiang Jintai will receive an upfront payment and milestone payments totaling approximately 510 million RMB for the collaboration [1] - The exclusive commercialization rights for the products in mainland China will be granted to Tibet Kangzhe, while RXILIENT will obtain exclusive licensing rights for the Asia-Pacific region, the Middle East, and North Africa [1] - There are uncertainties regarding the drug registration process and commercialization risks associated with the collaboration [1]

康哲药业公告，公司附属公司与中国生物制药企业智翔金泰签订合作协议，获得了唯康度塔单抗注射液 和斯乐韦米单抗注射液在中国大陆的独家商业化权，以及亚太地区和中东、北非的独家许可权。唯康度 塔单抗注射液用于破伤风治疗，斯乐韦米单抗注射液用于狂犬病治疗。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並表明概不就因本公告全部或任何部分內容而產生 或因倚賴該等內容而引致的任何損失承擔任何責任。 自願性及業務進展公告 就1類創新型治療用生物製品 重組人源化抗破傷風毒素單克隆抗體唯康度塔單抗注射液 及重組全人源抗狂犬病病毒雙特異性抗體斯樂韋米單抗注射液 簽訂合作協議 China Medical System Holdings Limited（「本公司」，連同其附屬公司統稱為「本 集團」）欣然宣佈，於二零二五年九月二十二日，本集團通過本公司附屬公司與重慶智 翔金泰生物製藥股份有限公司（「智翔金泰」）就用於破傷風的被動免疫適應症的1類 治療用生物製品唯康度塔單抗（GR2001）注射液（「唯康度塔單抗注射液」）及用於疑 似狂犬病病毒暴露後的被動免疫適應症的1類治療用生物製品斯樂韋米單抗（GR1801） 注射液（「斯樂韋米單抗注射液」）分別簽訂獨家合作協議（「協議」）。 根據協議，本集團獲得了唯康度塔單抗注射液及斯樂韋米單抗注射液在中國大陸的獨家 商業化權與除中國大陸之外的亞太地區及中東、北非的獨家許可權。合作 ...

Core Viewpoint - The company, Zhixiang Jintai, has entered into exclusive cooperation agreements with subsidiaries of Kangzhe Pharmaceutical Holdings and RXILIENT Medical for two monoclonal antibody injections, GR2001 and GR1801, which will provide significant financial benefits and exclusive commercialization rights in various regions [1][2]. Group 1: GR2001 Injection Agreement - Zhixiang Jintai will receive upfront payments and milestone payments totaling up to approximately 260 million RMB for the GR2001 injection [1] - Kangzhe Pharmaceutical will obtain exclusive commercialization rights for GR2001 in mainland China, while RXILIENT will have exclusive licensing rights for the Asia-Pacific region and the Middle East and North Africa [1] - The company will also earn revenue based on net sales adjustments from regions outside mainland China and will pay promotional service fees to Kangzhe Pharmaceutical based on sales revenue in mainland China [1] Group 2: GR1801 Injection Agreement - Zhixiang Jintai will receive upfront payments and milestone payments totaling up to approximately 250 million RMB for the GR1801 injection [2] - Kangzhe Pharmaceutical will gain exclusive commercialization rights for GR1801 in mainland China, while RXILIENT will have exclusive licensing rights for the Asia-Pacific region and the Middle East and North Africa [2] - Similar to the GR2001 agreement, the company will earn revenue based on net sales adjustments from regions outside mainland China and will pay promotional service fees to Kangzhe Pharmaceutical based on sales revenue in mainland China [2]

Core Viewpoint - The company, Zhixiang Jintai, has entered into exclusive cooperation agreements with Kangzhe Pharmaceutical Holdings and its subsidiary, Tibet Kangzhe Pharmaceutical Development, for the commercialization of two monoclonal antibody injections, GR2001 and GR1801, in various regions [1][2] Group 1: GR2001 Injection Agreement - Tibet Kangzhe will obtain exclusive commercialization rights for GR2001 in mainland China, while RXILIENT will have exclusive licensing rights for the Asia-Pacific region and the Middle East and North Africa, excluding mainland China [1] - The company will receive upfront payments and milestone payments totaling up to approximately 260 million RMB, along with sales revenue from mainland China and supply income based on net sales in the Asia-Pacific region and the Middle East and North Africa [1] - The company will pay promotional service fees to Tibet Kangzhe based on sales revenue in mainland China as per the agreement [1] Group 2: GR1801 Injection Agreement - Tibet Kangzhe will obtain exclusive commercialization rights for GR1801 in mainland China, while RXILIENT will have exclusive licensing rights for the Asia-Pacific region and the Middle East and North Africa, excluding mainland China [2] - The company will receive upfront payments and milestone payments totaling up to approximately 250 million RMB, along with sales revenue from mainland China and supply income based on net sales in the Asia-Pacific region and the Middle East and North Africa [2] - The company will pay promotional service fees to Tibet Kangzhe based on sales revenue in mainland China as per the agreement [2]

Core Insights - The company, Zhixiang Jintai, has signed exclusive cooperation agreements with Kangzhe Pharmaceutical Holdings and RXILIENT MEDICAL for two monoclonal antibody injections, GR2001 and GR1801, which will provide significant financial benefits and market access in various regions [1][2]. Group 1: Agreement Details - The agreements include upfront payments and milestone payments, with potential earnings of up to approximately RMB 260 million for GR2001 and RMB 250 million for GR1801 [1][2]. - Kangzhe will hold exclusive commercialization rights for both products in mainland China, while RXILIENT will have exclusive licensing rights in the Asia-Pacific region and the Middle East and North Africa [1][2]. Group 2: Product Information - GR2001 is a recombinant humanized monoclonal antibody targeting the C-terminal heavy chain of Tetanus Neurotoxin (TeNT), classified as a Class 1 therapeutic biological product, providing passive immunity by blocking TeNT entry into neurons [2]. - GR1801 is a recombinant fully human bispecific antibody targeting the glycoprotein of the Rabies Virus (RABV), also classified as a Class 1 therapeutic biological product, designed to prevent rabies by blocking the virus from binding to receptors before the active immunity from rabies vaccines takes effect [3].

Core Viewpoint - Zhixiang Jintai (688443.SH) has signed exclusive cooperation agreements with Tibet Kangzhe and RXILIENT for the commercialization of GR2001 and GR1801 monoclonal antibody injections, which is expected to positively impact the company's performance and long-term development [1] Group 1: Partnership Details - Tibet Kangzhe will obtain exclusive commercialization rights for the two products in mainland China [1] - RXILIENT will receive exclusive licensing rights for the Asia-Pacific region, as well as the Middle East and North Africa, excluding mainland China [1] Group 2: Financial Implications - Zhixiang Jintai will receive an upfront payment and milestone payments totaling approximately 510 million RMB [1] Group 3: Future Outlook - The cooperation is anticipated to have a positive effect on the company's performance and long-term growth [1] - There are uncertainties related to the drug registration process and commercialization risks [1]

重庆智翔金泰生物制药股份有限公司 自愿披露关于唯康度塔单抗注射液以及斯乐韦米单抗 注射液商业化合作的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 证券代码：688443 证券简称：智翔金泰 公告编号：2025-043 近日，重庆智翔金泰生物制药股份有限公司（以下简称"公司"、"智翔金泰"） 与康哲药业控股有限公司（以下简称"康哲药业"）之附属公司西藏康哲药业发展 有限公司（以下简称"西藏康哲"）和 RXILIENT MEDICAL PTE. LTD.（以下简称 "RXILIENT"）就唯康度塔单抗注射液（GR2001 注射液）以及斯乐韦米单抗注射 液（GR1801 注射液）分别签订独家合作协议（以下简称"协议"）。根据协议，公 司将获得首付款、里程碑付款并获得其商业化推广等服务，西藏康哲将获得上述两 款产品在中国大陆的独家商业化权，RXILIENT 将获得上述两款产品除中国大陆之 外的亚太地区及中东、北非的独家许可权。具体内容公告如下。 一、协议概述 根据《GR2001 注射液独家合作协议》，西藏康哲将获得唯康度塔 ...

Core Viewpoint - The company, Zhixiang Jintai, has signed exclusive cooperation agreements with Kangzhe Pharmaceutical and RXILIENT for the commercialization of two monoclonal antibody injections, GR2001 and GR1801, which will provide significant financial benefits and market access in various regions [1][2][3] Group 1: Agreements and Financial Terms - The agreements grant exclusive commercialization rights for GR2001 to Tibet Kangzhe in mainland China, while RXILIENT receives exclusive licensing rights for the Asia-Pacific region and the Middle East and North Africa [1] - Zhixiang Jintai will receive upfront and milestone payments totaling up to approximately 260 million RMB for GR2001, along with revenue from sales in mainland China and supply income based on net sales in other regions [1] - For GR1801, Tibet Kangzhe will also obtain exclusive commercialization rights in mainland China, with RXILIENT securing similar rights in the Asia-Pacific region and the Middle East and North Africa, and Zhixiang Jintai will receive payments up to approximately 250 million RMB [2] Group 2: Product Details - GR2001 is a recombinant humanized monoclonal antibody targeting the C-terminal of the Tetanus Neurotoxin (TeNT), classified as a Class 1 therapeutic biological product, providing passive immunity by blocking TeNT from entering neuronal cells [2] - GR1801 is a recombinant fully human bispecific antibody targeting the glycoprotein of the Rabies Virus (RABV), also classified as a Class 1 therapeutic biological product, designed to prevent rabies by blocking the virus's interaction with receptors before the vaccine can take effect [3]

Core Viewpoint - The company has entered into exclusive collaboration agreements for two monoclonal antibody injections, GR2001 and GR1801, with subsidiaries of Kangzhe Pharmaceutical and RXILIENT MEDICAL, indicating a strategic move to enhance its product portfolio and market presence in specific regions [1] Group 1 - The company will receive upfront payments and milestone payments as part of the collaboration agreements [1] - Kangzhe Pharmaceutical will obtain exclusive commercialization rights for the two products in mainland China [1] - RXILIENT MEDICAL will gain exclusive licensing rights for the products in the Asia-Pacific region, as well as the Middle East and North Africa [1]